Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000208227 | SCV000264138 | pathogenic | Proteinuria | 2015-09-28 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000786958 | SCV002018364 | pathogenic | Nephrotic syndrome, type 2 | 2019-06-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000786958 | SCV004049291 | pathogenic | Nephrotic syndrome, type 2 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000786958 | SCV004191557 | pathogenic | Nephrotic syndrome, type 2 | 2024-01-27 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003556262 | SCV004293850 | pathogenic | not provided | 2023-11-21 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 118 of the NPHS2 protein (p.Pro118Leu). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with clinical features of nephrotic syndrome (PMID: 15253708, 15264208). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 222762). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt NPHS2 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects NPHS2 function (PMID: 14675423, 24596097). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000786958 | SCV005633683 | pathogenic | Nephrotic syndrome, type 2 | 2024-02-10 | criteria provided, single submitter | clinical testing | |
Bioscientia Institut fuer Medizinische Diagnostik Gmb |
RCV000786958 | SCV000925863 | pathogenic | Nephrotic syndrome, type 2 | 2018-10-12 | no assertion criteria provided | clinical testing |